Format

Send to

Choose Destination
Rev Med Inst Mex Seguro Soc. 2018 Mar-Apr;56(2):180-185.

Gene signatures for breast cancer, clinical utility and therapeutic applications

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

1
Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 17, Servicio de Planificación Familiar. Ciudad de México, México v_vargas_aguilar@hotmail.com

Abstract

in English, Spanish

Gene signatures quantify hormone receptors and proliferation genes, combining multivariate prediction models. Hormone-negative tumors have greater proliferation and the prognostic value is limited. The first generation of prognostic signatures (Oncotype DX, MammaPrint, Genomic Degree Index) predict recurrence at 5 years. Subsequent tests (Prosigna, EndoPredict, Breast Cancer Index) have better prognostic value for recurrence and are predictive of early relapse. There are no useful prognostic genetic tests for hormone-negative tumors, or predictors of response to treatment. The recent expansion of high-performance technology platforms including the low-cost sequencing of tumor-derived DNA and circulating RNA and the reliable rapid quantification of microRNAs offer new opportunities to build prediction models.

KEYWORDS:

Breast Neoplasms; Chemotherapy, Adjuvant; Oncogenes

PMID:
29906029
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center